

Influenza Vaccine Product List and Age Groups --- United States, 2019-2020 Season¹

(DoD contracted vaccines are highlighted in yellow; *Direct Vendor Delivery (DVD) available vaccines are highlighted in orange)

| Manufacturer | Trade Name (vaccine abbreviation) ² | NDC | Presentation | Mercury (thimerosal) mcg Hg/0.5 mL | Ovalbumin mcg/0.5 mL | Age Group | CVX | CPT |
|------------------------|---|----------------------|--|------------------------------------|----------------------|-----------|-------|-------|
| Seqirus, Inc. | Afluria ^{®1,5} (IIV4) | 33332-0219-20 | 0.25 mL single-dose syringe | 0 | < 0.5 | 6-35 mos | 161 | 90685 |
| | | 33332-0319-01 | 0.5 mL single-dose syringe | 0 | < 1 | ≥ 3 yrs | 150 | 90686 |
| | | 33332-0419-10 | 5 mL multi-dose vial (0.25 mL dose) ⁴ | 12.25 | < 0.5 | 6-35 mos | 158 | 90687 |
| | | 33332-0419-10 | 5 mL multi-dose vial (0.5 mL dose) ⁴ | 24.5 | < 1 | ≥ 3 yrs | 158 | 90688 |
| | Fluad ^{®1,7} (aIIV3) | 70461-0019-03 | 0.5 mL single-dose syringe | 0 | < 0.4 | ≥ 65 yrs | 168 | 90653 |
| | Flucelvax ^{®1} (ccIIV4) | 70461-0319-03 | 0.5 mL single-dose syringe | 0 | ++ | ≥ 4 yrs | 171 | 90674 |
| 70461-0419-10 | | 5 mL multi-dose vial | 25 | ++ | 186 | | 90756 | |
| GlaxoSmithKline | Fluarix ^{®1} (IIV4) | 58160-0896-52 | 0.5 mL single-dose syringe ³ | 0 | ≤ 0.05 | ≥ 6 mos | 150 | 90686 |
| | FluLaval ^{®1} (IIV4) | 19515-0906-52 | 0.5 mL single-dose syringe ³ | 0 | ≤ 0.3 | ≥ 6 mos | 150 | 90686 |
| | | 19515-0897-11 | 5 mL multi-dose vial ^{3,4} | < 25 | ≤ 0.3 | | 158 | 90688 |
| Sanofi Pasteur, Inc. | Fluzone ^{®1} (IIV4) | 49281-0519-25 | 0.25 mL single-dose syringe ⁶ | 0 | §§ | 6-35 mos | 161 | 90685 |
| | | 49281-0419-50 | 0.5 mL single-dose syringe ⁶ | 0 | §§ | ≥ 6 mos | 150 | 90686 |
| | | 49281-0419-10 | 0.5 mL single-dose vial | 0 | §§ | | 150 | 90686 |
| | | 49281-0631-15 | 5 mL multi-dose vial (0.25 mL dose) | 12.5 | §§ | 6-35 mos | 158 | 90687 |
| | | 49281-0631-15 | 5 mL multi-dose vial (0.5 mL dose) | 25 | §§ | ≥ 6 mos | 158 | 90688 |
| | Fluzone [®] High-Dose ^{1,8} (IIV3-HD) | 49281-0405-65 | 0.5 mL single-dose syringe | 0 | §§ | ≥ 65 yrs | 135 | 90662 |
| Protein Sciences Corp. | FluBlok ^{®1} (RIV4) | 49281-0719-10 | 0.5 mL single-dose syringe | 0 | 0 | ≥ 18 yrs | 185 | 90682 |
| MedImmune | FluMist ^{®1,9} (LAIV4) | 66019-0306-10 | 0.2 mL single-use intranasal sprayer | 0 | ≤ 0.024 | 2-49 yrs | 149 | 90672 |

1. Check the Food and Drug Administration prescribing information for 2019-2020 seasonal influenza vaccines at www.fda.gov/BiologicsBloodVaccines/Vaccines/default.htm for the most complete and up-to-date information, including (but not limited to) indications, contraindications, warnings, and precautions.
 2. IIV3/IIV4 = egg-based trivalent/quadrivalent inactivated influenza vaccine (injectable); where necessary to refer to cell culture-based vaccine, the prefix "cc" is used (e.g., ccIIV4); RIV4 = quadrivalent recombinant hemagglutinin influenza vaccine (injectable); aIIV3 = adjuvanted trivalent inactivated influenza vaccine.
 3. FluLaval[®] (IIV4) and Fluarix[®] (IIV4) 0.5 mL dose is the same for adults and pediatrics.
 4. **Once the stoppers of the Afluria[®] and FluLaval[®] multi-dose vials are pierced the vial must be discarded within 28 days.**
 5. Afluria[®] is licensed for administration by PharmaJet[®] Stratis[®] Needle-Free Injection System for persons aged 18 through 64 years only.
 6. Fluzone[®] Quadrivalent is licensed for persons 6 months of age and older. Persons 6 to 35 months of age can receive either the 0.25 mL or the 0.5 mL dose.
 7. Fluad[®] includes the MF59C.1 adjuvant (MF59[®]), a squalene based oil-in-water emulsion.
 8. Trivalent inactivated vaccine high-dose: a 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).
 9. Recommendation of the CDC's Advisory Committee on Immunization Practices (ACIP) for the 2019-2020 influenza season, providers may choose to administer any licensed, age-appropriate influenza vaccine (IIV, recombinant influenza vaccine (RIV), or LAIV4). No preference is expressed for any influenza vaccine product.
- ++ Flucelvax[®] Quadrivalent was manufactured for the 2019-2020 influenza season using cell-based candidate vaccine virus (CVV) for all four influenza strains recommended by the World Health Organization (WHO); and is considered an egg-free product.
- §§ Available upon request from Sanofi Pasteur (1-800-822-2463 or MIS.emails@sanofipasteur.com).
- * Direct Vendor Delivery (DVD) vaccines are available for purchase by Medical Treatment Facilities. Refer to the 2019-2020 Seasonal Influenza DHA-IPM for information on the ordering process.